Injectable Paromomycin for Visceral Leishmaniasis in India | Zendy

Shyam Sundar | Zendy; T. K. Jha | Zendy; Chandreshwar Prasad Thakur | Zendy; Prabhat Kumar Sinha | Zendy; Sujit Bhattacharya | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Injectable Paromomycin for Visceral Leishmaniasis in India

Author(s) -

Shyam Sundar,

T. K. Jha,

Chandreshwar Prasad Thakur,

Prabhat Kumar Sinha,

Sujit Bhattacharya

Publication year - 2007

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa066536

Subject(s) - paromomycin , medicine , visceral leishmaniasis , leishmaniasis , aminoglycoside , traditional medicine , antibiotics , immunology , microbiology and biotechnology , biology

Visceral leishmaniasis (kala-azar) affects large, rural, resource-poor populations in South Asia, Africa, and Brazil. Safe, effective, and affordable new therapies are needed. We conducted a randomized, controlled, phase 3 open-label study comparing paromomycin, an aminoglycoside, with amphotericin B, the present standard of care in Bihar, India.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research